Live price temporarily unavailable.
Femasys (FEMY) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $1.04M | $1.18M | $1.21M | $1.07M | $1.63M | $2.29M |
| Growth (year over year) | — | +13.7% | +2.2% | −11.1% | +52.0% | +40.8% |
| Gross profit | $731.4K | $809.3K | $764.3K | $691.9K | $1.08M | $1.42M |
| Gross margin | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| Operating income | −$6.93M | −$8.34M | −$11.6M | −$14.5M | −$17.8M | −$17.6M |
| Operating margin | −668.0% | −706.7% | −961.7% | −1353.4% | −1091.8% | −767.0% |
| Net income | −$6.91M | −$7.54M | −$11.4M | −$14.2M | −$18.8M | −$18.6M |
| Net margin | −666.2% | −639.0% | −944.6% | −1329.1% | −1155.0% | −812.3% |
| EPS (diluted) | −$144.00 | −$22.40 | −$19.20 | −$18.60 | −$17.00 | −$9.40 |
| Balance sheet | ||||||
| Cash and equivalents | $3.32M | $24.8M | $13.0M | $21.7M | $3.45M | $9.27M |
| Total assets | $7.61M | $28.6M | $16.9M | $27.8M | $12.4M | $20.7M |
| Total liabilities | $4.08M | $2.24M | $1.65M | $9.40M | $10.1M | $14.9M |
| Shareholders' equity | −$51.8M | $26.3M | $15.2M | $18.4M | $2.30M | $5.87M |
| Cash flow | ||||||
| Operating cash flow | −$4.93M | −$7.93M | −$10.7M | −$11.3M | −$19.4M | −$18.7M |
| Capital expenditure | $8.35K | $306.9K | $407.5K | $143.9K | $761.7K | $525.0K |
| Free cash flow | −$4.94M | −$8.24M | −$11.1M | −$11.4M | −$20.2M | −$19.2M |
| Share buybacks | — | — | $0 | $230.0K | $60.8K | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $554.9K | $581.6K | $341.3K | $409.3K | $729.4K | $813.4K | $424.9K | $331.8K |
| Growth (year over year) | +127.1% | +172.9% | +25.9% | +84.8% | +31.4% | +39.9% | +24.5% | −18.9% |
| Gross profit | $364.1K | $389.2K | $224.0K | $251.1K | $435.6K | $510.3K | $266.3K | $189.4K |
| Gross margin | 65.6% | 66.9% | 65.6% | 61.4% | 59.7% | 62.7% | 62.7% | 57.1% |
| Operating income | −$5.12M | −$4.72M | −$5.46M | −$3.85M | −$3.65M | −$4.62M | −$4.22M | −$5.07M |
| Operating margin | −922.4% | −812.0% | −1600.1% | −941.1% | −500.9% | −568.3% | −994.0% | −1526.7% |
| Net income | −$5.41M | −$5.12M | −$5.90M | −$4.59M | −$4.19M | −$3.95M | $846.1K | −$4.47M |
| Net margin | −974.7% | −881.0% | −1727.9% | −1120.5% | −575.1% | −485.7% | 199.1% | −1346.8% |
| EPS (diluted) | −$4.80 | −$4.60 | −$4.60 | −$3.18 | −$2.00 | $0.38 | $0.00 | −$1.33 |
| Balance sheet | ||||||||
| Cash and equivalents | $7.61M | $3.45M | $3.82M | $3.22M | $4.57M | $9.27M | $5.39M | $1.44M |
| Total assets | $15.6M | $12.4M | $13.3M | $13.8M | $16.3M | $20.7M | $16.5M | $12.3M |
| Total liabilities | $9.62M | $10.1M | $11.3M | $12.3M | $11.7M | $14.9M | $9.21M | $8.26M |
| Shareholders' equity | $5.97M | $2.30M | $2.00M | $1.51M | $4.56M | $5.87M | $7.29M | $4.03M |
| Cash flow | ||||||||
| Operating cash flow | −$5.47M | −$5.07M | −$4.77M | −$4.35M | −$5.39M | −$4.19M | −$4.14M | −$3.94M |
| Capital expenditure | $407.9K | $106.8K | $96.6K | $94.2K | $194.3K | $139.8K | $79.1K | $9.40K |
| Free cash flow | −$5.88M | −$5.18M | −$4.86M | −$4.45M | −$5.58M | −$4.33M | −$4.22M | −$3.95M |
| Share buybacks | $0 | $30.1K | $161.8K | — | — | — | — | — |
From Femasys's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Femasys in our feed yet.